Preliminary Q4 2025 at LENZ Therapeutics (NASDAQ: LENZ) disclosed in 8-K

Rhea-AI Filing Summary

LENZ Therapeutics, Inc. filed a current report to say it has released a press release with certain preliminary, unaudited financial results for the three months ended December 31, 2025, along with recent corporate updates. These figures are still subject to the company’s normal accounting and annual audit procedures and may change once that work is completed.

The press release is provided as Exhibit 99.1 and is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

FALSE0001815776Solana BeachCalifornia00018157762026-01-072026-01-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2026

LENZ THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40532

84-4867570

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

201 Lomas Santa Fe Dr., Suite 300
Solana Beach, California						92075
(Address of principal executive offices)						(Zip code)

(858) 925-7000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.00001 per share

LENZ

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 7, 2026, LENZ Therapeutics, Inc. (“LENZ”) issued a press release reporting certain preliminary, unaudited financial results for the three months ended December 31, 2025 and recent corporate updates. The results included in the press release are preliminary, have not been audited and are subject to change upon completion of the Company’s accounting and annual audit procedures and are therefore subject to adjustment. Additional information and disclosures would be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Description
99.1						Press Release, dated January 7, 2026.
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 7, 2026

LENZ THERAPEUTICS, INC.
By:			/s/ Daniel Chevallard
Name:			Daniel Chevallard
Title:			Chief Financial Officer
			(Principal Financial and Accounting Officer)

FAQ

What did LENZ (LENZ) disclose in this January 7, 2026 8-K?

LENZ Therapeutics disclosed that it issued a press release containing certain preliminary, unaudited financial results for the three months ended December 31, 2025 and recent corporate updates.

Which period do LENZ Therapeutics preliminary results cover?

The preliminary, unaudited financial results discussed by LENZ Therapeutics cover the three months ended December 31, 2025.

Are LENZ Therapeutics reported results audited or final?

No. LENZ Therapeutics states the results are preliminary and unaudited, and they are subject to change upon completion of the companys accounting and annual audit procedures.

How did LENZ Therapeutics provide the detailed information mentioned in the 8-K?

LENZ Therapeutics provided the detailed preliminary results and corporate updates in a press release furnished as Exhibit 99.1 to the report.

Is the LENZ Therapeutics press release considered filed for liability purposes?

The company specifies that the information under Item 2.02 and Exhibit 99.1 is furnished, not filed, so it is not subject to Section 18 of the Exchange Act or incorporated into other filings unless specifically referenced.

Who signed the LENZ Therapeutics 8-K covering the preliminary results?

The report was signed on behalf of LENZ Therapeutics, Inc. by Daniel Chevallard, Chief Financial Officer and Principal Financial and Accounting Officer.